Kyle Rose

Work

Analyst Kyle Rose works at CANACCORD and is focused on the Healthcare sector with 470 price targets and ratings documented since 2012 spanning on 24 stocks. Analyst's average stock valuation to be materialised ratio is 49.54% with an average time for price targets to be met of 154.64 days.

Most recent stock forecast was given on BVS, Bioventus Inc - Class A at 09-Nov-2022.

Kyle Rose best performing recommendations are on TELA (TELA BIO INC.).
The best stock recommendation documented was for XENT at 1/11/2021. The price target of $25 was fulfilled within 2 days with a profit of $2.78 (12.51%) receiving and performance score of 62.56.

Average potential price target upside

ATEC AXGN CFMS DXCM FNA INMD KRMD NUVA PODD SIBN SIEN SPNE SYK TELA XENT ZBH SKIN GMED MSON RSLS SENS OBLN BVS SNN
ATEC AXGN CFMS DXCM FNA INMD KRMD NUVA PODD SIBN SIEN SPNE SYK TELA XENT ZBH SKIN GMED MSON RSLS SENS OBLN BVS SNN